Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2017

Be the first to review this product

Availability: In stock

$2,995.00

Quick Overview

The Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2017 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies.

Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2017
Publication date Sep 2017
Publisher Current Partnering
Number of pages 2,000+
Report edition 2
Product code CP2064
ISBN n/a
Product type Research report
Available formats PDF

* Required Fields

$2,995.00

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2017 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals and agreements entered into by the worlds leading life science companies.

 

This report provides details of the latest collaborative R&D deals announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date with the latest information, the report provides details of collaborative R&D deals from 2012 to 2017.

 

There has been a long standing willingness for parties to enter collaborative R&D deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

 

Collaborative R&D is a specific type of partnering deal whereby the parties to the deal agree to collaborate on the research and development and subsequently commercialize a compound, product or technology.

 

There are several forms of a collaborative R&D deal; A traditional collaborative R&D arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for agreed payments and royalties on subscequent sales of product(s) derived from the intellectual property.

 

In more recent times, licensing is often the outcome of a successful period of collaborative R&D on the research and development of a technology or compound, resulting in a product which can be commercialized. In this situation, the collaborative R&D agreement governs who has permission to commercialize and what payments are due should commercialization proceed.

 

The report provides a detailed understand and analysis of how and why companies enter collaborative R&D deals. The majority of deals are multicomponent whereby the licensee retains either a right or option to license to comoercialize the resultant product of the research collaboration. There are also numerous pure licensing deals whereby the products originator takes on a development/commercialization partner in order to maximize a technologies/products prospects.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

This report contains a comprehensive listing of all collaborative R&D deals announced since 2012 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaborative R&D contract documents as submitted to the Securities Exchange Commission by companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of collaborative R&D dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in collaborative R&D as well as a discussion on the merits of the type of deal.

 

Chapter 3 provides an overview of the structure of collaborative R&D deals. The chapter includes numerous case studies to enable understanding of both pure collaborative R&D deals and multicomponent deals where collaborative R&D forms a part.

 

Chapter 4 provides a review of the leading collaborative R&D deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 5 provides a review of the top 50 most active biopharma companies in collaborative R&D. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 6 provides a comprehensive review of collaborative R&D financials for deals announced since 2012, including headline value, upfront, milestone payments and royalty rates, providing both benchmark data and access to individual deal financials.

 

Chapter 7 provides a comprehensive and detailed review of collaborative R&D deals signed and announced since 2012 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

 

The report also includes numerous table and figures that illustrate the trends and activities in collaborative R&D dealmaking since 2012.

 

In addition, a comprehensive appendix is provided organized by company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about collaborative R&D partnering in the research, development and commercialization of technologies and products.

 

Key benefits

 

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2017 provides the reader with the following key benefits:

 

  • In-depth understanding of collaborative R&D deal trends since 2012
  • Analysis of the structure of collaborative R&D agreements with numerous real life case studies
  • Comprehensive listing of over 4,500 collaborative R&D deals since 2012, together with deal terms, value and press release
  • Comprehensive access to actual collaborative R&D contracts entered into by the world’s life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a collaborative R&D agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2017 is intended to provide the reader with an in-depth understanding of the collaborative R&D trends and structure of deals entered into by leading life science companies worldwide.         

 

Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2017 includes:

 

  • Trends in collaborative R&D dealmaking in the biopharma industry since 2012
  • Analysis of collaborative R&D deal structure
  • Case studies of real-life collaborative R&D deals
  • Comprehensive listing of over 4,500 collaborative R&D deals since 2012
  • Access to collaborative R&D contract documents
  • Key financial benchmarks for headline, upfront, milestone and royalty rates
  • The leading collaborative R&D deals by value since 2012
  • Most active collaborative R&D dealmakers since 2012
  • The leading collaborative R&D partnering resources

 

In Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2017 available deals and contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

 

The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2017 report provides comprehensive access to available contract documents for licensing deals. Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How do milestone align with clinical stage development phases?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2017 report provides the reader with the following key benefits:

 

  • In-depth understanding of collaborative R&D deal trends since 2012
  • Analysis of the structure of collaborative R&D agreements with numerous real life case studies
  • Comprehensive listing of all collaborative R&D deals since 2012, together with deal terms, value and press release
  • Comprehensive access to actual collaborative R&D contracts entered into by the world’s life science companies
  • Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates
  • Insight into the terms included in a collaborative R&D agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in collaborative R&D dealmaking

 

2.1. Introduction

2.2. Definition of collaborative R&D partnering

2.3. Success factors for collaborative R&D deals

2.4. When collaborative R&D can be useful

2.5. Attributes of collaborative R&D deals

2.6. Trends in collaborative R&D deals since 2012

2.6.1. Collaborative R&D dealmaking by year, 2012 to 2017

2.6.2. Collaborative R&D dealmaking by phase of development, 2012 to 2017

2.6.3. Collaborative R&D dealmaking by industry sector, 2012 to 2017

2.6.4. Collaborative R&D dealmaking by therapy area, 2012 to 2017

2.6.5. Collaborative R&D dealmaking by technology type, 2012 to 2017

2.6.6. Collaborative R&D dealmaking by most active company, 2012 to 2017

2.7. The future of collaborative R&D deals

 

Chapter 3 – Overview of collaborative R&D deal structure

 

3.1. Introduction

3.2. Pure versus multi-component collaborative R&D deals

3.3. Pure collaborative R&D agreement structure

3.3.1. Example collaborative R&D agreements

3.3.1.a. Case study 1: Marinus Pharmaceuticals - NovaMedica

3.3.1.b. Case study 2: Idenix Pharmaceuticals – Janssen Pharmaceuticals

3.4. Collaborative R&D as part of a wider alliance agreement

3.4.1. Example collaborative R&D agreements and their licensing clauses

3.4.1.a. Case study 3: 4D Molecular Therapeutics – UniQure

3.4.1.b. Case study 4: Kyowa Hakko Kirin – Ultragenyx Pharmaceuticals

3.4.2. Example licensing option right clauses in collaborative R&D deals

3.4.2.a. Case study 5: Forest Laboratories - Trevena

3.4.2.b. Case study 6: Abbvie – Receptos

 

Chapter 4 – Leading collaborative R&D deals

 

4.1. Introduction           

4.2. Top collaborative R&D deals by value

 

Chapter 5 – Top 50 most active collaborative R&D dealmakers

 

5.1. Introduction

5.2. Top 50 most active collaborative R&D dealmakers

 

Chapter 6 – Collaborative R&D deal term financials

 

6.1. Introduction

6.2. Collaborative R&D partnering headline values

6.3. Collaborative R&D deal upfront payments

6.4. Collaborative R&D deal milestone payments

6.5. Collaborative R&D royalty rates

 

Chapter 7 – Collaborative R&D contract directory 2012 - 2017

 

7.1. Introduction

7.2. Collaborative R&D deals with contracts 2012 to 2017

 

Appendices

 

Appendix 1 – Collaborative R&D dealmaking by companies A-Z

Appendix 2 – Collaborative R&D dealmaking by industry sector

Appendix 3 – Collaborative R&D dealmaking by stage of development

Appendix 4 – Collaborative R&D dealmaking by therapy area

Appendix 5 – Collaborative R&D dealmaking by technology type

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

TABLE OF FIGURES

 

Figure 1: Definition of collaborative R&D

Figure 2: Situations where collaborative R&D can prove useful

Figure 3: Key attributes of a collaborative R&D deal

Figure 4: Trends in Collaborative R&D deal announcements, 2012 to 2017

Figure 5: Collaborative R&D deals signed at each phase of development, 2012 to 2017

Figure 6: Collaborative R&D deals by industry sector, 2012 to 2017

Figure 7: Collaborative R&D deals by therapy area, 2012 to 2017

Figure 8: Collaborative R&D deals by technology type, 2012 to 2017

Figure 9: Top 50 most active collaborative R&D dealmakers, 2012 to 2017

Figure 10: Collaborative R&D agreements – what should a contract include?

Figure 11: Components of the collaborative R&D deal structure

Figure 12: Top collaborative deals by value 2012 to 2017

Figure 13: Most active collaborative R&D dealmakers 2012 to 2017

Figure 14: Collaborative R&D deals with a headline value

Figure 15: Collaborative R&D deals with an upfront value

Figure 16: Collaborative R&D deals with a milestone value

Figure 17: Collaborative R&D deals with a royalty rate value

Pricing options

  • $2,995: single-user
  • $4,495: multi-user
  • $8,995: single site license
  • $14,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

You may also be interested in the following product(s)

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2010-2017

$2,995.00
Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2017

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2017

$2,995.00
   

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.

© 2017 Wildwood Ventures Ltd.